Streetbeat News

Price Targets

CNXC

Canaccord Genuity analyst Joseph Vafi maintains a Buy rating on Concentrix (NASDAQ:CNXC) but lowers the price target from $125 to $100.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 2:31 pm

IONS

RBC Capital analyst Luca Issi has reiterated an Outperform rating for Ionis Pharmaceuticals, maintaining a price target of $70.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 2:22 pm

SBUX

Starbucks shares rise as Bernstein upgrades the stock from Market Perform to Outperform, increasing the price target from $92 to $115.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 2:20 pm

RGEN

RBC Capital has reiterated its 'Outperform' rating for Repligen (NASDAQ:RGEN) and maintained a price target of $205.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 2:19 pm

VAC

Barclays analyst Brandt Montour maintains an Equal-Weight rating on Marriott Vacations (NYSE:VAC) but lowers the price target from $82 to $74.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 2:19 pm

FTV

Barclays analyst Julian Mitchell maintains an Overweight rating on Fortive (NYSE:FTV) and raises the price target from $94 to $96.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 2:17 pm

FLUT

Barclays analyst Brandt Montour has maintained an Overweight rating on Flutter Entertainment and raised the price target from $263 to $275.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 2:16 pm

RARE

RBC Capital has reiterated its Outperform rating for Ultragenyx Pharmaceutical, maintaining a price target of $77.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 2:13 pm